The US Food and Drug Administration (FDA) has warned that sodium-glucose cotransporter-2 (SGLT2) inhibitors used to treat type 2 diabetes may lead to ketoacidosis (DKA) requiring hospitalization.
The warning includes the SGLT2 inhibitors canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance), as well as three combination products that include an SGLT2 inhibitor: canagliflozin plus metformin (Invokamet), dapagliflozin plus metformin extended release (Xigduo XR), and empagliflozin plus linagliptin (Glyxambi).
Diabetic ketoacidosis (DKA) is a life-threatening medical emergency. It needs prompt diagnosis and treament in a hospital setting. Otherwise, there is a high risk of mortality.
Other previously known side-effects from these drugs include:
· Excessive urination
· Low blood pressure
· Increase in Potassium level in the blood (which can be life-threatening
· Kidney dysfunction
· Increase in LDL cholesterol
· Urinary tract infections
· Genital fungal infections
Excerpts from Dr. Zaidi's book,
"Reverse Your Type 2 Diabetes Scientifically."
Excerpts from Dr. Zaidi's book, "Reverse Your Type 2 Diabetes Scientifically."
This article was written by Sarfraz Zaidi, MD, FACE. Dr. Zaidi specializes in Diabetes, Endocrinology and Metabolism.
Dr. Zaidi is a former assistant Clinical Professor of Medicine at UCLA and Director of the Jamila Diabetes and Endocrine Medical Center in Thousand Oaks, California.
Copyright © All rights reserved.